Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Ischemic Stroke ll: Pathophysiology

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Ischemic Stroke l: Introduction

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.

Hemorrhagic Stroke ll: Pathophysiology

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

The New England journal of medicine·2026

Same author

Left atrial enlargement and 1-year cerebrovascular events in subjects without atrial fibrillation: A prospective cohort study.

European journal of internal medicine·2026

Same author

Observational, Multicenter study on long-term Effectiveness and tolerability of aliROcumab (OMERO): an Italian real-life experience.

International journal of cardiology. Cardiovascular risk and prevention·2026

Same author

Optimising the Caravaggio score: developing a more universally applicable and comprehensive venous thromboembolism risk stratification tool. Author's reply.

European journal of internal medicine·2026

Same author

Right ventricular dysfunction on echocardiography to predict mortality in acute pulmonary embolism: an individual patient data meta-analysis.

Journal of thrombosis and haemostasis : JTH·2025

Same author

Point-of-care ultrasonography (POCUS): a substantial help for the internists with some caveats.

European journal of internal medicine·2025

Search research articles

Related Experiment Video

Updated: May 27, 2026

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Published on: December 15, 2023

Gene-drug interaction in stroke.

Serena Amici¹, Maurizio Paciaroni, Giancarlo Agnelli

¹Stroke Unit, Division of Cardiovascular Medicine, University of Perugia, Santa Maria della Misericordia Hospital, Sant'Andrea delle Fratte, 06126 Perugia, Italy.

Stroke Research and Treatment

|December 3, 2011

Summary

This summary is machine-generated.

Pharmacogenetics in stroke care explores how genetic variations affect drug responses. While some gene-drug interactions show promise, genotype-guided treatment isn't yet standard practice for stroke patients.

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Related Experiment Videos

Last Updated: May 27, 2026

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Published on: December 15, 2023

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Area of Science:

Neuroscience and Genetics
Pharmacology and Therapeutics

Background:

Stroke is a leading cause of death and long-term neurological disability.
Genetic factors play a significant role in stroke development and treatment response.
Pharmacogenetics investigates the link between genetic variability and drug efficacy/toxicity.

Purpose of the Study:

To review the implications of pharmacogenetics in stroke management.
To examine genetic influences on the effectiveness and toxicity of key stroke medications.

Main Methods:

Review of existing literature on pharmacogenetics of stroke.
Analysis of data concerning antihypertensives, statins, antiplatelets, anticoagulants, and recombinant tissue plasminogen activator.
Evaluation of studied genetic polymorphisms and their association with drug-gene interactions in stroke.

Main Results:

Several genetic polymorphisms have been identified with potential positive drug-gene interactions in stroke.
Evidence supporting the superiority of genotype-guided treatment over clinical approaches remains insufficient.
Specific drug classes reviewed include antihypertensives, statins, antiplatelets, anticoagulants, and thrombolytics.

Conclusions:

Pharmacogenetic insights offer potential for personalized stroke therapy.
Current evidence does not support routine genotype-guided treatment for stroke.
Further research is needed to validate the clinical utility of genetic profiling in stroke pharmacotherapy.